Welcome to our dedicated page for Inspira Tech news (Ticker: IINNW), a resource for investors and traders seeking the latest updates and insights on Inspira Tech stock.
Inspira Technologies Oxy B.H.N. Ltd. reports developments in life-support and respiratory treatment technologies for critical care patients. Company news commonly covers the INSPIRA™ ART100 system, an FDA-cleared cardiopulmonary bypass system that adds oxygen to blood and removes carbon dioxide before returning blood to the patient, as well as product features for clinical workflow, alarm management and emergency uptime.
Recurring updates also address U.S. deployment activity, medical-device production arrangements, VORTX™ blood oxygenation delivery technology, the HYLA™ blood sensor, Israeli AMAR certification for extracorporeal membrane oxygenation and cardiopulmonary bypass procedures, and board-level governance changes.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Inspira Technologies OXY B.H.N. Ltd. (NASDAQ:IINN)(NASDAQ:IINNW) is set to present at the 2023 Planet MicroCap Showcase in Las Vegas on April 26, 2023, at 14:30 CST. Joe Hayon, President and Co-Founder, will lead the presentation. Interested parties can access the live presentation via the provided webcast link. Registration for the event is necessary, which can be done here. Additionally, one-on-one virtual meetings can be scheduled with Joe throughout May by using this link. Inspira Technologies focuses on innovative respiratory treatments, particularly its Augmented Respiration Technology, aimed at improving patient outcomes while minimizing the use of invasive mechanical ventilation.
Inspira Technologies OXY B.H.N. Ltd. (Nasdaq: IINN, IINNW) reported its financial results for the year ended December 31, 2022. The company has $13.9 million in cash, a decrease from $23.7 million in 2021, with shareholders' equity falling to $12.8 million from $20.3 million. R&D expenses increased to $8 million from $3.9 million in the previous year. The net loss showed improvement at $10.3 million compared to $17 million in 2021. The company plans to submit its ALICE device for FDA approval in H2 2023 and is conducting clinical studies for its HYLA blood sensor. Inspira continues to advance its INSPIRA ART system aimed at non-invasive respiratory treatment.